Clinical study of thalidomide combined with temozolomide in the postoperative treatment of patients with glioblastoma: a single arm, open, multicenter phase II clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17010963

Enrollment

Unknown

Registered

2017-03-23

Start date

2017-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Interventions

Experimental group: Thalidomide

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years old; 2. Patients with glioblastoma (WHO grade IV) who underwent surgical resection and pathological diagnosis; 3. KPS=60; 4. Expectation of life>3 months; 5. No chemotherapy or other anti-cancer therapy before; 6. Written informed consent was obtained.

Exclusion criteria

Exclusion criteria: 1. Women of childbearing age and recent fertility programs, pregnant or lactating women; 2. Patients with mechanical obstruction of digestive tract; 3. VTE; 4. Other history of malignant disease for the past 5 years; 5. History of uncontrolled seizures, central nervous system disorders or mental disorders; 6. Serious heart disease; 7. Organ transplantation requires immunosuppressive therapy; 8. A person with severe uncontrolled repeated infection or other serious uncontrolled accompanying disease; 9. The baseline blood routine and biochemical parameters were not up to standard; 10. Allergic to any of the ingredients used in the study.

Design outcomes

Primary

Measure	Time frame
1 year OS;	—

Secondary

Measure	Time frame
PFS;mOS;Toxicities;	—

Countries

China

Contacts

Public ContactJunxin Wu

Fujian Cancer Hospital

junxinwu@126.com+86 13635293859

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026